Soliris (Eculizumab) for PNH

Overview
Soliris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to reduce the destruction of red blood cells in people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is also referred to by its drug name, eculizumab.

Soliris is a complement inhibitor. This means that it helps control the immune system to prevent it from harming the body’s healthy cells. Soliris is also a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Soliris is believed to work by binding to complement protein C5, part of the immune system that attacks red blood cells in PNH and prevents it from being activated.

How do I take it?
Soliris is administered by intravenous infusion once every two weeks after initial loading doses (the first doses given at the start of treatment). The medication comes as a single-dose vial.

Side effects
The FDA-approved label for Soliris lists common side effects including headache, back pain, nausea, and symptoms of upper respiratory tract infection.

Rare but serious side effects listed for Soliris include severe infusion reactions and increased risk of meningococcal infections, which affect the lining of the brain or spinal cord and may be life-threatening or fatal.

For more details about this treatment, visit:

Soliris (Eculizumab) — Alexion
https://alexion.com/en/our-medicines/medicines/...